Predicting Chest Wall Pain From Lung Stereotactic Body Radiotherapy for Different Fractionation Schemes

被引:43
作者
Woody, Neil M. [1 ]
Videtic, Gregory M. M. [1 ]
Stephans, Kevin L. [1 ]
Djemil, Toufik [1 ]
Kim, Yongbok [2 ]
Xia, Ping [1 ]
机构
[1] Cleveland Clin, Dept Radiat Oncol, Taussig Canc Ctr, Cleveland, OH 44195 USA
[2] Allegheny Gen Hosp, Dept Radiat Oncol, Pittsburgh, PA 15212 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2012年 / 83卷 / 01期
关键词
Stereotactic body radiation therapy; Chest wall pain; Modified effective uniform dose; Stage I lung cancer; Radiobiologic effect; RADIATION-THERAPY; CANCER; TRIAL;
D O I
10.1016/j.ijrobp.2011.06.1971
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Recent studies with two fractionation schemes predicted that the volume of chest wall receiving >30 Gy (V30) correlated with chest wall pain after stereotactic body radiation therapy (SBRT) to the lung. This study developed a predictive model of chest wall pain incorporating radiobiologic effects, using clinical data from four distinct SBRT fractionation schemes. Methods and Materials: 102 SBRT patients were treated with four different fractionations: 60 Gy in three fractions, 50 Gy in five fractions, 48 Gy in four fractions, and 50 Gy in 10 fractions. To account for radiobiologic effects, a modified equivalent uniform dose (mEUD) model calculated the dose to the chest wall with volume weighting. For comparison, V30 and maximum point dose were also reported. Using univariable logistic regression, the association of radiation dose and clinical variables with chest wall pain was assessed by uncertainty coefficient (U) and C statistic (C) of receiver operator curve. The significant associations from the univariable model were verified with a multivariable model. Results: 106 lesions in 102 patients with a mean age of 72 were included, with a mean of 25.5 (range, 12-55) months of follow-up. Twenty patients reported chest wall pain at a mean time of 8.1 (95% confidence interval, 6.3-9.8) months after treatment. The mEUD models, V30, and maximum point dose were significant predictors of chest wall pain (p < 0.0005). mEUD improved prediction of chest wall pain compared with V30 (C = 0.79 vs. 0.77 and U = 0.16 vs. 0.11). The mEUD with moderate weighting (a = 5) better predicted chest wall pain than did mEUD without weighting (a = 1) (C = 0.79 vs. 0.77 and U = 0.16 vs. 0.14). Body mass index (BMI) was significantly associated with chest wall pain (p = 0.008). On multivariable analysis, mEUD and BMI remained significant predictors of chest wall pain (p = 0.0003 and 0.03, respectively). Conclusion: mEUD with moderate weighting better predicted chest wall pain than did V30, indicating that a small chest wall volume receiving a high radiation dose is responsible for chest wall pain. Independently of dose to the chest wall, BMI also correlated with chest wall pain. (C) 2012 Elsevier Inc.
引用
收藏
页码:427 / 434
页数:8
相关论文
共 21 条
  • [1] [Anonymous], 1995, Ann. Thorac. Surg, DOI 10.1016/0003-4975
  • [2] A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION
    CHARLSON, ME
    POMPEI, P
    ALES, KL
    MACKENZIE, CR
    [J]. JOURNAL OF CHRONIC DISEASES, 1987, 40 (05): : 373 - 383
  • [3] CHEST WALL VOLUME RECEIVING &gt;30 GY PREDICTS RISK OF SEVERE PAIN AND/OR RIB FRACTURE AFTER LUNG STEREOTACTIC BODY RADIOTHERAPY
    Dunlap, Neal E.
    Cai, Jing
    Biedermann, Gregory B.
    Yang, Wensha
    Benedict, Stanley H.
    Sheng, Ke
    Schefter, Tracey E.
    Kavanagh, Brian D.
    Larner, James M.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 76 (03): : 796 - 801
  • [4] RANDOMIZED TRIAL OF LOBECTOMY VERSUS LIMITED RESECTION FOR T1 N0 NON-SMALL-CELL LUNG-CANCER
    HOLMES, CE
    RUCKDESCHEL, JC
    JOHNSTON, M
    THOMAS, PA
    DESLAURIERS, J
    GROVER, FL
    HILL, LD
    FELD, R
    GINSBERG, RJ
    MOUNTAIN, CF
    DZUIBAN, S
    KIELY, M
    MCKNEALLY, MF
    MOORES, DWO
    RAMNES, C
    WAGNER, H
    BUNN, P
    CHU, H
    DIENHART, D
    HAZUKA, M
    KINZIE, J
    SORENSEN, J
    VANCE, V
    BRAUN, T
    HOPEMAN, A
    KANE, M
    RUSS, P
    WHITMAN, GJR
    FALL, SM
    HANSEN, DP
    HENDERSON, RH
    MONCRIEF, CL
    PAULING, F
    SIMS, J
    TELL, D
    WISELYCARR, S
    ABERNATHY, CM
    CLARK, DA
    MCCROSKEY, B
    MOORE, G
    MOORE, F
    MYERS, A
    WHITE, M
    BROOKS, RJ
    BULL, M
    JOHNSON, FB
    NEIMYR, M
    PAQUETTE, FR
    SACCOMANNO, G
    LAD, T
    [J]. ANNALS OF THORACIC SURGERY, 1995, 60 (03) : 615 - 622
  • [5] ACUTE SKIN TOXICITY FOLLOWING STEREOTACTIC BODY RADIATION THERAPY FOR STAGE I NON-SMALL-CELL LUNG CANCER: WHO'S AT RISK?
    Hoppe, Bradford S.
    Laser, Benjamin
    Kowalski, Alex V.
    Fontenla, Sandra C.
    Pena-Greenberg, Elizabeth
    Yorke, Ellen D.
    Lovelock, D. Michael
    Hunt, Margie A.
    Rosenzweig, Kenneth E.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (05): : 1283 - 1286
  • [6] Can stereotactic fractionated radiation therapy become the standard of care for early stage non-small cell lung carcinoma
    Nguyen, Nam P.
    Garland, Linda
    Welsh, James
    Hamilton, Russ
    Cohen, Deirdre
    Vinh-Hung, Vincent
    [J]. CANCER TREATMENT REVIEWS, 2008, 34 (08) : 719 - 727
  • [7] Stereotactic hypofractionated radiotherapy for stage I non-small cell lung cancer -: Mature results for medically inoperable patients
    Nyman, J
    Johansson, KA
    Hultén, U
    [J]. LUNG CANCER, 2006, 51 (01) : 97 - 103
  • [8] Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: Updated results of 257 patients in a Japanese multi-institutional study
    Onishi, Hiroshi
    Shirato, Hiroki
    Nagata, Yasushi
    Hiraoka, Masahiro
    Fujino, Masaharu
    Gomi, Kotaro
    Niibe, Yuzuru
    Karasawa, Katsuyuki
    Hayakawa, Kazushige
    Takai, Yoshihiro
    Kimura, Tomoki
    Takeda, Atsuya
    Ouchi, Atsushi
    Hareyama, Masato
    Kokubo, Masaki
    Hara, Ryusuke
    Itami, Jun
    Yamada, Kazunari
    Araki, Tsutomu
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (07) : S94 - S100
  • [9] Universal survival curve and single fraction equivalent dose: Useful tools in understanding potency of ablative radiotherapy
    Park, Clint
    Papiez, Lech
    Zhang, Shichuan
    Story, Michael
    Timmerman, Robert D.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 70 (03): : 847 - 852
  • [10] Method to account for dose fractionation in analysis of IMRT plans: Modified equivalent uniform dose
    Park, CS
    Kim, Y
    Lee, N
    Bucci, KM
    Quivey, JM
    Verhey, LJ
    Xia, P
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 62 (03): : 925 - 932